Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2019

Open Access 01-12-2019 | Pancreatectomy | Research

Effect of clinical status on survival in patients with borderline or locally advanced pancreatic adenocarcinoma

Authors: Pauline Duconseil, Jonathan Garnier, Victoria Weets, Jacques Ewald, Ugo Marchese, Marine Gilabert, Laurence Moureau-Zabotto, Flora Poizat, Marc Giovannini, Jean-Robert Delpero, Olivier Turrini

Published in: World Journal of Surgical Oncology | Issue 1/2019

Login to get access

Abstract

Objective

To determine the effect of clinical status (weight variation and performance status [PS]) at diagnosis and during induction treatment on resectability and overall survival (OS) rates in patients with borderline resectable (BRPC) or locally advanced pancreatic cancer (LAPC).

Methods

From 2005 to 2017, 454 consecutive patients were diagnosed with LAPC or BRPC. We evaluated the PS (0–1 or 2–3), body mass index at diagnosis, and weight loss (WL) > 5% at initial staging and after induction treatment and separated continuous weight loss (CWL) from weight stabilization.

Results

A total of 294 patients (64.8%) presented with WL, and 57 patients (12.6%) presented with a PS of 2–3. At restaging, 60 patients (13.2%) presented with CWL. Independent factors that poorly influenced the OS were a PS of 2–3 at diagnosis (P < .01), CWL at restaging (P < .01), and absence of resection (P < .01). Factors independently impeding resection were LAPC (P < .01), PS > 1 at diagnosis (P < .01), and CWL (P = .01). In total, 142 patients (31.3%) underwent pancreatectomy. Independent factors that poorly influenced the OS in the resected group were PS > 0 at diagnosis (P = .01) and obesity (P < .01). For the 312 unresected cancer patients (68.7%), CWL (P < .01) was identified as an independent factor that poorly influenced the OS.

Conclusion

Clinical parameters that are easy to measure and monitor are independent factors of poor prognosis. The variation of weight during the induction treatment, more than WL at diagnosis, significantly precluded resection and was an independent factor of shorter OS in unresected patients.
Literature
1.
go back to reference Splinter TA. Cachexia and cancer: a clinician’s view. Ann Oncol. 1992;3(Suppl 3):25–7.CrossRef Splinter TA. Cachexia and cancer: a clinician’s view. Ann Oncol. 1992;3(Suppl 3):25–7.CrossRef
2.
go back to reference Bye A, Jordhoy MS, Skjegstad G, et al. Symptoms in advanced pancreatic cancer are of importance for energy intake. Support Care Cancer. 2013;21:219–27.CrossRef Bye A, Jordhoy MS, Skjegstad G, et al. Symptoms in advanced pancreatic cancer are of importance for energy intake. Support Care Cancer. 2013;21:219–27.CrossRef
3.
go back to reference La Torre M, Ziparo V, Nigri G, et al. Malnutrition and pancreatic surgery: prevalence and outcomes. J Surg Oncol. 2013;107:702–8.CrossRef La Torre M, Ziparo V, Nigri G, et al. Malnutrition and pancreatic surgery: prevalence and outcomes. J Surg Oncol. 2013;107:702–8.CrossRef
4.
go back to reference Ryan DP, Grossbard ML. Pancreatic Cancer: Local success and distant failure. Oncologist. 1998;3:178–88.PubMed Ryan DP, Grossbard ML. Pancreatic Cancer: Local success and distant failure. Oncologist. 1998;3:178–88.PubMed
5.
go back to reference Falconer JS, Fearon KC, Plester CE, et al. Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg. 1994;219:325–31.CrossRef Falconer JS, Fearon KC, Plester CE, et al. Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg. 1994;219:325–31.CrossRef
6.
go back to reference Kim SY, Wie GA, Lee WJ, et al. Changes in dietary intake, body weight, nutritional status, and metabolic rate in a pancreatic cancer patient. Clin Nutr Res. 2013;2:154–8.CrossRef Kim SY, Wie GA, Lee WJ, et al. Changes in dietary intake, body weight, nutritional status, and metabolic rate in a pancreatic cancer patient. Clin Nutr Res. 2013;2:154–8.CrossRef
7.
go back to reference Witvliet-van Nierop JE, Lochtenberg-Potjes CM, Wierdsma NJ, et al. Assessment of nutritional status, digestion and absorption, and quality of life in patients with locally advanced pancreatic cancer. Gastroenterol Res Pract. 2017;2017:6193765.CrossRef Witvliet-van Nierop JE, Lochtenberg-Potjes CM, Wierdsma NJ, et al. Assessment of nutritional status, digestion and absorption, and quality of life in patients with locally advanced pancreatic cancer. Gastroenterol Res Pract. 2017;2017:6193765.CrossRef
8.
go back to reference Danai LV, Babic A, Rosenthal MH, et al. Altered exocrine function can drive adipose wasting in early pancreatic cancer. Nature. 2018;558:600–4.CrossRef Danai LV, Babic A, Rosenthal MH, et al. Altered exocrine function can drive adipose wasting in early pancreatic cancer. Nature. 2018;558:600–4.CrossRef
9.
go back to reference Andreyev HJ, Norman AR, Oates J, Cunningham D. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer. 1998;34:503–9.CrossRef Andreyev HJ, Norman AR, Oates J, Cunningham D. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer. 1998;34:503–9.CrossRef
10.
go back to reference Gianotti L, Besselink MG, Sandini M, et al. Nutritional support and therapy in pancreatic surgery: a position paper of the International Study Group on Pancreatic Surgery (ISGPS). Surgery. 2018;164:1035–48.CrossRef Gianotti L, Besselink MG, Sandini M, et al. Nutritional support and therapy in pancreatic surgery: a position paper of the International Study Group on Pancreatic Surgery (ISGPS). Surgery. 2018;164:1035–48.CrossRef
11.
go back to reference Bozzetti F, Mariani L. Perioperative nutritional support of patients undergoing pancreatic surgery in the age of ERAS. Nutrition. 2014;30:1267–71.CrossRef Bozzetti F, Mariani L. Perioperative nutritional support of patients undergoing pancreatic surgery in the age of ERAS. Nutrition. 2014;30:1267–71.CrossRef
12.
go back to reference Pausch T, Hartwig W, Hinz U, et al. Cachexia but not obesity worsens the postoperative outcome after pancreatoduodenectomy in pancreatic cancer. Surgery. 2012;152:S81–8.CrossRef Pausch T, Hartwig W, Hinz U, et al. Cachexia but not obesity worsens the postoperative outcome after pancreatoduodenectomy in pancreatic cancer. Surgery. 2012;152:S81–8.CrossRef
13.
go back to reference Hendifar AE, Chang JI, Huang BZ, et al. Cachexia, and not obesity, prior to pancreatic cancer diagnosis worsens survival and is negated by chemotherapy. J Gastrointest Oncol. 2018;9:17–23.CrossRef Hendifar AE, Chang JI, Huang BZ, et al. Cachexia, and not obesity, prior to pancreatic cancer diagnosis worsens survival and is negated by chemotherapy. J Gastrointest Oncol. 2018;9:17–23.CrossRef
14.
go back to reference Moningi S, Walker AJ, Hsu CC, et al. Correlation of clinical stage and performance status with quality of life in patients seen in a pancreas multidisciplinary clinic. J Oncol Pract. 2015;11:e216–21.CrossRef Moningi S, Walker AJ, Hsu CC, et al. Correlation of clinical stage and performance status with quality of life in patients seen in a pancreas multidisciplinary clinic. J Oncol Pract. 2015;11:e216–21.CrossRef
15.
go back to reference Sandini M, Patino M, Ferrone CR, et al. Association between changes in body composition and neoadjuvant treatment for pancreatic cancer. JAMA Surg. 2018;153:809–15.CrossRef Sandini M, Patino M, Ferrone CR, et al. Association between changes in body composition and neoadjuvant treatment for pancreatic cancer. JAMA Surg. 2018;153:809–15.CrossRef
16.
go back to reference Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55.CrossRef Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55.CrossRef
17.
go back to reference Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15:1028–61.CrossRef Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15:1028–61.CrossRef
18.
go back to reference Schwarz L, Lupinacci RM, Svrcek M, et al. Para-aortic lymph node sampling in pancreatic head adenocarcinoma. Br J Surg. 2014;101:530–8.CrossRef Schwarz L, Lupinacci RM, Svrcek M, et al. Para-aortic lymph node sampling in pancreatic head adenocarcinoma. Br J Surg. 2014;101:530–8.CrossRef
19.
go back to reference Turrini O, Ewald J, Barbier L, et al. Should the portal vein be routinely resected during pancreaticoduodenectomy for adenocarcinoma? Ann Surg. 2013;257:726–30.CrossRef Turrini O, Ewald J, Barbier L, et al. Should the portal vein be routinely resected during pancreaticoduodenectomy for adenocarcinoma? Ann Surg. 2013;257:726–30.CrossRef
20.
go back to reference Chang DK, Johns AL, Merrett ND, et al. Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol. 2009;27:2855–62.CrossRef Chang DK, Johns AL, Merrett ND, et al. Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol. 2009;27:2855–62.CrossRef
21.
go back to reference van Roessel S, Kasumova GG, Verheij J, et al. International validation of the eighth edition of the American Joint Committee on Cancer (AJCC) TNM staging system in patients with resected pancreatic cancer. JAMA Surg. 2018;153:e183617.CrossRef van Roessel S, Kasumova GG, Verheij J, et al. International validation of the eighth edition of the American Joint Committee on Cancer (AJCC) TNM staging system in patients with resected pancreatic cancer. JAMA Surg. 2018;153:e183617.CrossRef
22.
go back to reference Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.CrossRef Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.CrossRef
23.
go back to reference Mariani L, Lo Vullo S, Bozzetti F, Group S.W. Weight loss in cancer patients: a plea for a better awareness of the issue. Support Care Cancer. 2012;20:301–9.CrossRef Mariani L, Lo Vullo S, Bozzetti F, Group S.W. Weight loss in cancer patients: a plea for a better awareness of the issue. Support Care Cancer. 2012;20:301–9.CrossRef
24.
go back to reference Parker NH, Ngo-Huang A, Lee RE, et al. Physical activity and exercise during preoperative pancreatic cancer treatment. Support Care Cancer. 2018;27(6):2275–84.CrossRef Parker NH, Ngo-Huang A, Lee RE, et al. Physical activity and exercise during preoperative pancreatic cancer treatment. Support Care Cancer. 2018;27(6):2275–84.CrossRef
25.
go back to reference Davidson W, Ash S, Capra S, et al. Weight stabilisation is associated with improved survival duration and quality of life in unresectable pancreatic cancer. Clin Nutr. 2004;23:239–47.CrossRef Davidson W, Ash S, Capra S, et al. Weight stabilisation is associated with improved survival duration and quality of life in unresectable pancreatic cancer. Clin Nutr. 2004;23:239–47.CrossRef
26.
go back to reference Yuan C, Bao Y, Wu C, et al. Prediagnostic body mass index and pancreatic cancer survival. J Clin Oncol. 2013;31:4229–34.CrossRef Yuan C, Bao Y, Wu C, et al. Prediagnostic body mass index and pancreatic cancer survival. J Clin Oncol. 2013;31:4229–34.CrossRef
27.
go back to reference Lomberk G, Blum Y, Nicolle R, et al. Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. Nat Commun. 2018;9:1978.CrossRef Lomberk G, Blum Y, Nicolle R, et al. Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. Nat Commun. 2018;9:1978.CrossRef
28.
go back to reference Gerber MH, Underwood PW, Judge SM, et al. Local and systemic cytokine profiling for pancreatic ductal adenocarcinoma to study cancer cachexia in an era of precision medicine. Int J Mol Sci. 2018;19;(12). Gerber MH, Underwood PW, Judge SM, et al. Local and systemic cytokine profiling for pancreatic ductal adenocarcinoma to study cancer cachexia in an era of precision medicine. Int J Mol Sci. 2018;19;(12).
29.
go back to reference Isaji S, Mizuno S, Windsor JA, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018;18:2–11.CrossRef Isaji S, Mizuno S, Windsor JA, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018;18:2–11.CrossRef
Metadata
Title
Effect of clinical status on survival in patients with borderline or locally advanced pancreatic adenocarcinoma
Authors
Pauline Duconseil
Jonathan Garnier
Victoria Weets
Jacques Ewald
Ugo Marchese
Marine Gilabert
Laurence Moureau-Zabotto
Flora Poizat
Marc Giovannini
Jean-Robert Delpero
Olivier Turrini
Publication date
01-12-2019
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2019
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-019-1637-1

Other articles of this Issue 1/2019

World Journal of Surgical Oncology 1/2019 Go to the issue